Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$1.95 → $1.95 · observed estimates
Embecta Corp. (EMBC)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$6.33-2.91%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.95 → 1.95 EPS · FY ending Sep 30, 2028 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for EMBC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete $100M share repurchase program and maintain low dividend | The dividend cut to $0.01 per share boosts financial flexibility. | Intact | Dividend rises above $0.05 or buyback program stalls | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$1.95 → $1.95 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 24, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a smaller-cap healthcare business with a value-oriented setup, rather than a proven, steady compounder. The long-term thesis is intact, but earnings quality is fragile and the evidence behind that view has medium confidence.
EMBC is described as cheap versus peers, while the valuation model has low confidence. The pricing evidence calls the setup justified and shows low fragility, so it does not point to a market assumption of a fully expensive, weak, and turbulent business.
Near-term results have been strong overall, though recent earnings have been erratic, with a miss in May followed by a beat and a guidance raise in August. Management is progressing on the Owen Mumford integration, product launches, and debt reduction; near-term risks include a reversal in guidance and weaker employment conditions.
Over the next one to three years, the thesis hinges on maintaining guidance credibility and turning the acquisition and product launches into sustained business progress. Continued strength from healthcare peers could support the sector backdrop, while weakening jobs data could increase pressure on cyclical healthcare names.
The 1-3 year view remains intact, supported by recent performance and management execution, but fragile earnings quality and elevated risk make delivery the key test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Embecta completed the acquisition of Owen Mumford to expand its product range. |
| Improving |
| Acquisition integration delays or failure to realize synergies |
Integration completed 2026-05-15; Q2 2026 earnings beat Owen Mumford acquisition completed May 2026. Q2 2026 earnings beat offsets Q1 miss and S&P credit rating cut. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating margin near 22.75% next quarter | The company targets about $1.025 billion revenue and 22.75% profit margin next quarter. | Under Pressure | Operating margin falls below 20% next quarter | Operating margin: 17.92% FY2026-Q3; GAAP. Published target: ~22.75%. Target period ends 2026-09-30; this observation covers 2026-Q3. Aug 7, 202617.924181 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “Mr. Kurdikar continued, "Given our results, we have initiated a review of our cost structure and organizational footprint and expect to communicate findings and any resulting actions to investors once that process is complete.” Delivery assessment Nov 4, 2026 |
Revenue reaches about $1.025 billion next quarter | The company targets about $1.025 billion revenue and 22.75% profit margin next quarter. | Broken | Revenue falls below $1.0 billion next quarter | Revenue: $271.7M FY2026-Q3; GAAP. Published target: ~$1.025 billion. Target period ends 2026-09-30; this observation covers 2026-Q3. Aug 7, 2026271,700,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.09B → $1.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-02 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-03 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-04 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-05 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-06 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-07 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-08 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-09 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-10 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-11 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-12 | $1.95 | $1,087,266,667 | 3 / 3 |
| 2026-10-13 | $1.95 | $1,087,276,667 | 3 / 3 |
| 2026-10-14 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-15 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-16 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-17 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-18 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-19 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-20 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-21 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-22 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-23 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-24 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-25 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-26 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-27 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-28 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-29 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-30 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-10-31 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-11-01 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-11-02 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-11-03 | $1.95 | $1,087,278,400 | 3 / 3 |
| 2026-11-04 | $1.95 | $1,087,278,400 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.